Latest Press Releases
AimwellBio's live signal intelligence engine is now tracking 13 source streams in real time - FDA actions, drug recalls, clinical trials, patent filings, global outbreaks, and regulatory divergence. It's running right now. The only question is whether you're seeing what it sees.
Aimwell Partners Inc. (OTC:AIMN) expands its healthcare intelligence platform to address one of the fastest-growing risks in modern medicine - clinical decisions influenced by unverified or AI-generated information.
AI is making life-or-death decisions in healthcare, and nobody is checking if the answers are real. AimwellBio is the first platform that does. FHIN founding cohort now forming.
Joint Venture to Produce Hydrogen, Ammonia, Nitrogen, and Urea, Expanding Global Clean-Energy Footprint
Hydrogen in 2025: A Key Player in Energy Transition